Soleus Capital Management’s NeoGenomics NEO Stock Holding History

Soleus Capital Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Sell	175,000 -252,504	-59%	-$2.66M	0.05%	82
2025 Q4	$5.03M	Buy	+427,504	New	+$4.61M	0.19%	67
2022 Q2	–	Sell	-460,000	Closed	-$5.59M	–	79
2022 Q1	$5.59M	Buy	+460,000	New	+$9.68M	0.72%	41
2021 Q4	–	Sell	-190,556	Closed	-$9.19M	–	83
2021 Q3	$9.19M	Sell	190,556 -161,451	-46%	-$7.47M	1.43%	21
2021 Q2	$15.9M	Buy	352,007 +306,056	+666%	+$13.6M	2.45%	11
2021 Q1	$2.22M	Hold	45,951	–	–	0.4%	49
2020 Q4	$2.47M	Buy	+45,951	New	+$2.08M	0.33%	32

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Soleus Capital Management's NEO Position: Q1 2026 in Review

Soleus Capital Management reduced its NeoGenomics (NEO) stake by 59% in Q1 2026, selling an estimated $2.66M and leaving 175,000 shares worth $1.3M. The position accounts for 0.05% of the portfolio, ranked #82.

Soleus Capital Management first reported a position in NEO in Q4 2020 and has held it in 7 quarters since. The position peaked at $15.9M in Q2 2021. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

Soleus Capital Management held 175,000 shares of NeoGenomics worth $1.3M as of Q1 2026.
Soleus Capital Management sold 252,504 NeoGenomics shares in Q1 2026, an estimated $2.66M.
NeoGenomics made up 0.05% of Soleus Capital Management's portfolio in Q1 2026, its #82 holding.
Soleus Capital Management first reported a position in NeoGenomics in Q4 2020 and has held it in 7 quarters since.
Soleus Capital Management's NeoGenomics position peaked at $15.9M in Q2 2021.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.